Сегодня 20 сентября 2019
Медикус в соцсетях
 
Задать вопрос

ЗАДАТЬ ВОПРОС РЕДАКТОРУ РАЗДЕЛА (ответ в течение нескольких дней)

Представьтесь:
E-mail:
Не публикуется
служит для обратной связи
Антиспам - не удалять!
Ваш вопрос:
Получать ответы и новости раздела
20 мая 2002 00:00   |   William L. Holman, MD*a, James E. Davies, MDa, Barry K. Rayburn, MDb, David C. McGiffin, MDa, Brian A. Foley, MDc, Raymond L. Benza, MDc, Robert C. Bourge, MDb, Peggy Blood, RNc, James K. Kirklin, MDa

Treatment of end-stage heart disease with outpatient ventricular assist devices

Background. Initiating outpatient therapy with ventricular assist devices (VAD) was important in the progress of mechanical circulatory support. This article reviews our experience with VAD therapy from the start of our outpatient program until the present.
Methods. Medical records of patients who received a Thoratec para-corporeal VAD, HeartMate vented electrical VAD, or HeartMate pneumatic VAD between 12/1/97 and 9/1/01 were reviewed. Variables included age, type of devices, total duration of VAD support, discharge status, duration of outpatient support, outcome (transplanted, died on support, ongoing), in-hospital length of stay after transplantation, and complications during VAD support.
Results. There were 53 device implants in 46 patients. The cumulative patient-days of VAD support was 7,468 (mean duration of support, 138 ± 195 days; median, 95 days; range, 2 to 948 days). Twenty of the 46 patients were discharged with a VAD. The cumulative outpatient days was 3,600 (mean outpatient duration, 157 ± 164 days; median, 83 days; maximum, 560 days). Of the 20 outpatients, 11 received cardiac transplantation, 5 died, and 4 are ongoing as of 9/1/01. Major complications that occurred in the outpatient setting included 5 deaths after hospital readmission (1 sepsis, 1 conduit tear, 3 neurologic events); 4 device infections (3 sepsis, 1 pouch infection); and 3 device malfunctions that required reoperation for pump replacement (1 HeartMate pneumatic and 2 HeartMate vented electrical). No deaths occurred in an outpatient setting.
Conclusions. Ventricular assist devices effectively support outpatients for months to years. The anticipated time for postoperative recovery and VAD training before discharge is approximately 14 to 21 days, although shorter times may be possible in the future. Establishing a successful outpatient VAD program is a crucial step toward VAD as definitive therapy for end-stage heart disease.

Поделиться:




Комментарии
Смотри также
20 мая 2002  |  00:05
Endothelial cell injury induced by preservation solutions: a confocal microscopy study
Background. We evaluated the effects of standard preservation solutions on cultured human greater saphenous vein endothelial cells. Methods. Endothelial cells (eight strains) were preincubated
20 мая 2002  |  00:05
Catheter pericardiocentesis for delayed tamponade after cardiac valve operation
Background. Late tamponade is a rare cause of morbidity and mortality after cardiac valve operation. We describe our recent experience with this entity. Methods. This is a single institution,
20 мая 2002  |  00:05
Liberal use of delayed sternal closure for postcardiotomy hemodynamic instability
Background. The purpose of this retrospective study was to evaluate the current incidence, survival, and predictors of mortality for open chest management at our center. Methods. Our database
20 мая 2002  |  00:05
Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury
Background. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that ischemic events are decreased in patients receiving angiotensin-converting enzyme (ACE) inhibitors. This study
20 мая 2002  |  00:05
Myocardial infarction scar plication in the rat: cardiac mechanics in an animal model for surgical procedures
Backgund. The immediate effects of surgical reduction of left ventricle cavity on cardiac mechanics have not been well defined. Methods. Cardiac mechanics were analyzed before and after myocardial